Biotron Ltd
ASX:BIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
V
|
Versarien PLC
SWB:9RV
|
UK |
Biotron Ltd
Total Liabilities
Biotron Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biotron Ltd
ASX:BIT
|
Total Liabilities
AU$1.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
15%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Liabilities
$207.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
|
|
CSL Ltd
ASX:CSL
|
Total Liabilities
$19.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Liabilities
AU$1.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Liabilities
AU$748.6m
|
CAGR 3-Years
62%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Liabilities
AU$11.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
27%
|
CAGR 10-Years
30%
|
|
Biotron Ltd
Glance View
Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.
See Also
What is Biotron Ltd's Total Liabilities?
Total Liabilities
1.2m
AUD
Based on the financial report for Dec 31, 2025, Biotron Ltd's Total Liabilities amounts to 1.2m AUD.
What is Biotron Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
15%
Over the last year, the Total Liabilities growth was 131%. The average annual Total Liabilities growth rates for Biotron Ltd have been 13% over the past three years , 11% over the past five years , and 15% over the past ten years .
